5 Patents
- US125772832026Knockdown or Knockout of One or More of TAP2, NLRC5, B2m, TRAC, RFX5, RFXAP and RFXANK to Mitigate T Cell Recognition of Allogeneic Cell Products
Allogene Therapeutics, Inc.
0 cites - US125772902026Fasl Expression and Fasr Gene Knockout to Protect Therapeutic Cells from Allogeneic Rejection and Activation-induced Cell Death
Allogene Therapeutics, Inc.
0 cites - 0 cites
- US122153472025Chimeric Antigen Receptors with Enhanced Signaling and Activities and Uses Thereof
Allogene Therapeutics, Inc.
0 cites - 0 cites